Alnylam: AMVUTTRA Revenue Tops $1 Billion, But Pent-Up Demand Normalization Triggers Guidance Cut
Alnylam reported Q2 2026 AMVUTTRA net product revenue of $1.01B, up 106% year over year, and total quarterly product revenue of $1.17B. Combined TTR revenue was $1.03B. Despite results, Alnylam cut 2026 TTR product revenue guidance to $4.2B-$4.5B and total net product revenue to $4.7B-$5.1B, citing normalization of second-line demand. Total Q2 revenue rose to $1.29B.
How this was made
The 30-second read
Why it matters
The key market signal is management lowering 2026 TTR product revenue and total net product revenue ranges, attributing it to moderation in U.S. second-line cardiomyopathy demand after an initial pent-up launch period.
Market read
Strong Q2 execution and profitability were offset by a management-guided normalization in second-line demand, leading to a material 2026 revenue outlook reset.
What to watch
Royalty guidance was raised (to $575M-$625M) and AMVUTTRA international expansion (Spain launch, China/Macao commercialization agreement) could support a faster-than-guided ramp in later quarters.
Background
Alnylam’s AMVUTTRA is the only approved therapy across the full ATTR amyloidosis spectrum and is delivered via quarterly subcutaneous injection.
Ticker impact
Alnylam reported AMVUTTRA Q2 net product revenue of $1.01B but cut full-year 2026 TTR and total product revenue guidance due to normalized second-line demand.
Bias to downside or higher volatility as traders reprice 2026 TTR/product revenue trajectory; upside possible if collaboration/royalty uplift offsets the cut.
The article’s newest decision is management lowering 2026 TTR product revenue range to $4.2B-$4.5B and total net product revenue to $4.7B-$5.1B, explicitly tied to second-line demand normalization.
Market effects
ATTR amyloidosis commercial execution narrative shifts from pent-up demand to normalized second-line volume, a read-through for other TTR franchise investors.
U.S. cardiomyopathy second-line demand normalization is the stated driver, making U.S. sales assumptions more sensitive than international.
Royalty and collaboration dynamics (Leqvio sales, ZENITH reimbursable activity) partially offset product softness, affecting how investors model RNAi platform cash flow.
Counterpoint
The guidance midpoint still implies ~75% TTR revenue growth vs 2025, so the cut may reflect timing normalization rather than durable demand deterioration.
Key entities
- companyAlnylam Pharmaceuticals
Reported AMVUTTRA Q2 revenue above $1B and cut full-year 2026 TTR and product revenue guidance due to normalized second-line demand.
- productAMVUTTRA
ATTR amyloidosis therapy; Q2 net product revenue was $1.01B and drove most of Alnylam’s product revenue.
- productONPATTRO
TTR franchise transition product; Q2 revenue declined 65% to about $18M as revenue shifted to AMVUTTRA.
- companyNovartis
Leqvio sales growth was cited as a driver of Alnylam’s higher royalty revenue in the quarter.
- companyRegeneron
Lower collaboration revenue was partly attributed to Alnylam’s collaboration with Regeneron.
